ArticleFrontiers in cardiovascular medicine2025
Specific associations of serum FGF23 and soluble Klotho with different types of left ventricular hypertrophy in hypertensive peritoneal dialysis patients: a cross-sectional study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the association between serum fibroblast growth factor 23 (FGF23) and soluble α-Klotho levels with left ventricular hypertrophy (LVH) in hypertensive patients undergoing peritoneal dialysis (PD). We also sought to evaluate their potential as biomarkers of left ventricular remodelling and to analyze potential non-linear relationships with the left ventricular mass index (LVMI), including subgroup differences. Methods: In this cross-sectional study, 124 hypertensive PD patients were enrolled. Serum concentrations of FGF23 and soluble α-Klotho were measured via enzyme-linked immunosorbent assay (ELISA). Echocardiography was used to assess left ventricular structure and define LVH. Multivariate logistic regression analysis was performed to evaluate the independent associations of these biomarkers with LVH. A restricted cubic spline (RCS) model was employed to explore non-linear relationships with LVMI. Results: The prevalence of LVH was 62.9%. After adjusting for gender, systolic blood pressure C-reactive, protein, haemoglobin, serum calcium, ejection fraction, serum phosphorus, and parathyroid hormone, multivariate analysis identified soluble α-Klotho as an independent protective factor against LVH (OR = 0.415, 95% CI: 0.247-0.643, Conclusion: Among hypertensive PD patients, serum soluble α-Klotho is an independent protective biomarker for LVH, while elevated FGF23 levels are associated with an increased risk of LVH, suggesting an interaction between the two. FGF23 demonstrates a non-linear association with LVMI, which is modified by age and gender. Concurrent measurement of FGF23 and soluble α-Klotho may help identify patients at high risk for cardiovascular remodelling, thereby informing risk stratification and personalized management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.